Breast cancer
Conditions
Interventions
Non-secondary prevention group:Loperamide
secondary prevention group(A):Loperamide
secondary prevention group(B):Loperamide and Live Combined Bifidobacterium
secondary prevention group (C):Loperamide and Montmorillonite powder
secondary prevention group (D):Non-prevention
Sponsors
Tianjin Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. One of the following two conditions: (1) Patients who plan to take pyrrolidine >= 21 days; (2) At present, patients with grade 3 diarrhea or grade 3 diarrhea accompanied with complications after taking pyrrolidine plan to take pyrrolidine >= 21 days; 2. Patients over 18 years old; 3. Patients with ECoG PS 0-2; 4. Patients with life expectancy >= 6 months; 5. Volunteer to join the study, sign informed consent, have good compliance and be willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients who may be allergic to pyrrolidine or excipients; 2. Patients with multiple factors affecting the absorption of oral drugs, such as inability to swallow, nausea and vomiting, etc.; 3. Patients with biliary obstruction; 4. Patients participating in other diarrhea related clinical trials; 5. Pregnant and lactating women, women with fertility and positive baseline pregnancy test, or women of childbearing age who are unwilling to take effective contraceptive measures during the whole test period; 6. According to the judgment of the researcher, patients with serious hazards to the safety of patients, or accompanying diseases that affect the completion of the study (including but not limited to severe hypertension, severe diabetes, etc., which cannot be controlled by drugs); 7. Any other circumstances in which the patient is not considered suitable for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stool frequency; | — |
Countries
China
Contacts
Public ContactHong Liu
Tianjin Cancer Hospital
Outcome results
None listed